The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease

Neuroscience Letters

Volumn 427, Issue 3, 2007, Pages 127-131

  Giedraitis, Vilmantas ^a   Sundelöf, Johan ^a   Irizarry, Michael C ^b   Gårevik, Nina ^c   Hyman, Bradley T ^b   Wahlund, Lars Olof ^c   Ingelsson, Martin ^a   Lannfelt, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Amyloid beta; APOE; Case control studies; Cerebrospinal fluid; Mild cognitive impairment (MCI)

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENILE PLAQUE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 35448942648     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.09.023     Document Type: Article

References (27)

1. Assini A., Cammarata S., Vitali A., Colucci M., Giliberto L., Borghi R., Inglese M.L., Volpe S., Ratto S., Dagna-Bricarelli F., Baldo C., Argusti A., Odetti P., Piccini A., and Tabaton M. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 63 (2004) 828-831
2. Basun H., Nilsberth C., Eckman C., Lannfelt L., and Younkin S. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement. Geriatr. Cogn. Disord. 14 (2002) 156-160
3. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1 (2004) 213-225
4. DeMattos R.B., Bales K.R., Parsadanian M., O'Dell M.A., Foss E.M., Paul S.M., and Holtzman D.M. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81 (2002) 229-236
5. Dooneief G., Marder K., Tang M.X., and Stern Y. The Clinical Dementia Rating scale: community-based validation of "profound' and "terminal' stages. Neurology 46 (1996) 1746-1749
6. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., and Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64 (2007) 343-349
7. Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., and Holtzman D.M. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9 (2002) 305-318
8. Freeman S.H., Raju S., Hyman B.T., Frosch M.P., and Irizarry M.C. Plasma Abeta levels do not reflect brain Abeta levels. J. Neuropathol. Exp. Neurol. 66 (2007) 264-271
9. Fryer J.D., Simmons K., Parsadanian M., Bales K.R., Paul S.M., Sullivan P.M., and Holtzman D.M. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25 (2005) 2803-2810
10. Fukumoto H., Tennis M., Locascio J.J., Hyman B.T., Growdon J.H., and Irizarry M.C. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol. 60 (2003) 958-964
11. Ghersi-Egea J.F., Gorevic P.D., Ghiso J., Frangione B., Patlak C.S., and Fenstermacher J.D. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67 (1996) 880-883
12. Hixson J.E., and Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31 (1990) 545-548
13. Jensen M., Schroder J., Blomberg M., Engvall B., Pantel J., Ida N., Basun H., Wahlund L.O., Werle E., Jauss M., Beyreuther K., Lannfelt L., and Hartmann T. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol. 45 (1999) 504-511
14. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., and Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21 (2001) 372-381
15. Lanz T.A., Hosley J.D., Adams W.J., and Merchant K.M. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide (LY-411575). J. Pharmacol. Exp. Ther. 309 (2004) 49-55
16. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K., Eikenberg O., Antz C., Krause W.R., Reulbach U., Kornhuber J., and Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol. Aging 25 (2004) 273-281
17. Matsumoto Y., Yanase D., Noguchi-Shinohara M., Ono K., Yoshita M., and Yamada M. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 23 (2007) 241-245
18. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34 (1984) 939-944
19. Mehta P.D., and Pirttila T. Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease. Neurodegener. Dis. 2 (2005) 242-245
20. Mehta P.D., Pirttila T., Patrick B.A., Barshatzky M., and Mehta S.P. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 304 (2001) 102-106
21. Panza F., D'Introno A., Colacicco A.M., Capurso C., Del Parigi A., Caselli R.J., Pilotto A., Argentieri G., Scapicchio P.L., Scafato E., Capurso A., and Solfrizzi V. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am. J. Geriatr. Psychiatry 13 (2005) 633-644
22. Pesaresi M., Lovati C., Bertora P., Mailland E., Galimberti D., Scarpini E., Quadri P., Forloni G., and Mariani C. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 27 (2006) 904-905
23. Peskind E.R., Li G., Shofer J., Quinn J.F., Kaye J.A., Clark C.M., Farlow M.R., DeCarli C., Raskind M.A., Schellenberg G.D., Lee V.M., and Galasko D.R. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch. Neurol. 63 (2006) 936-939
24. Siemers E.R., Quinn J.F., Kaye J., Farlow M.R., Porsteinsson A., Tariot P., Zoulnouni P., Galvin J.E., Holtzman D.M., Knopman D.S., Satterwhite J., Gonzales C., Dean R.A., and May P.C. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66 (2006) 602-604
25. Sobow T., Flirski M., Kloszewska I., and Liberski P.P. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta. Neurobiol. Exp. (Wars) 65 (2005) 117-124
26. Vanderstichele H., Van Kerschaver E., Hesse C., Davidsson P., Buyse M.A., Andreasen N., Minthon L., Wallin A., Blennow K., and Vanmechelen E. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7 (2000) 245-258
27. Wahlund L.O., Pihlstrand E., and Jönhagen M.E. Mild cognitive impairment: experience from a memory clinic. Acta Neurol. Scand. 179 (2003) 21-24